We have located links that may give you full text access.
Journal Article
Review
The possible role of interleukin-35 and its therapeutic potential in pemphigus.
International Immunopharmacology 2017 January
Pemphigus is an autoimmune disease that causes blistering and is life-threatening if left untreated. Nowadays, finding a promising treatment for pemphigus remains a serious challenge. Various treatments are currently recommended to treat this disease, but they rarely lead to complete and durable remission. Regulatory cells appear to have a critical role in numerous autoimmune diseases, so it is possible that promotion of these cells may induce remission. This study presents a new approach to treating pemphigus that has not been discussed to date. This approach introduces interleukin (IL)-35 as a new treatment for pemphigus. This cytokine could induce two different types of regulatory cell, including IL-35-that produces induced regulatory T cells and IL-35+ regulatory B cells, which could suppress both effector T cells and effector B cells. It seems that IL-35 may act as an efficient therapeutic strategy for pemphigus. It probably limits progression of the disease and may even contribute to long-lasting remission. However, further study is required to evaluate the efficacy and safety of treating pemphigus with IL-35.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app